lunes, 9 de julio de 2018

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model | JAMA Oncology | JAMA Network

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model | JAMA Oncology | JAMA Network

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast CancerA Life-Table Model

JAMA Oncol. Published online July 5, 2018. doi:10.1001/jamaoncol.2018.1901

No hay comentarios:

Publicar un comentario